Published Date: 02 Mar 2023
Two new findings led by Cedars-Sinai researchers suggest that stem cell therapy can help speed up and speed healing of bone and muscle injuries.
Read Full NewsResearchers at The University of Texas MD Anderson Cancer Center, in collaboration with BostonGene, conducted the largest and most comprehensive molecular analysis of renal medullary carcinoma (RMC), a rare and aggressive ...
The U.S. Food and Drug Administration approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma.
1.
Anti-PD-L1 Plus Targeted Agent No Better Than Chemo for Resistant NSCLC
2.
For patients with prostate cancer, long-term follow-up helps identify treatment side effects.
3.
fresh E. Coli Outbreak: ECMO Redefining Death and Bringing Universal Blood One Step Nearer.
4.
NEJM: Fluorescent guide can aid in the detection of tumors that are still present after breast cancer surgery.
5.
Chemo-Free Triplet Yields 68% Response Rate in Richter Transformation
1.
Chemotherapy Advances: Albumin I.V., Trastuzumab, Liposomal Doxorubicin & More
2.
Phosphate Vs. Phosphorus: What Is The Difference?
3.
Cancer in 2024: Global Trends, Challenges, and Innovations for Healthcare Professionals
4.
Exploring New Treatment Options for Hemophilia: A Journey into the Unknown
5.
Understanding the Role of CA 19-9 in Cancer Diagnosis and Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
2.
Efficient Management of First line ALK-rearranged NSCLC - Part III
3.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
4.
Should We Use DARA Up Front As First-Line Therapy in MM? - Part II
5.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation